| 1. |
|
|
| 2. |
- Spandau, Ulrich, et al.
(author)
-
Inadequate laser coagulation is an important cause of treatment failure in Type 1 retinopathy of prematurity.
- 2020
-
In: Acta Ophthalmologica. - : Wiley. - 1755-375X .- 1755-3768. ; 98:8, s. 795-799
-
Journal article (peer-reviewed)abstract
- PURPOSE OF THE STUDY: To examine the cause of treatment failures in Type 1 retinopathy of prematurity (ROP).PATIENTS AND METHODS: The medical charts of all infants with disease persistence after laser treatment at Uppsala University Hospital, Sweden, during a 10-year period (2009-2019) were reviewed. RetCam photography and angiography were used to document the retinal appearance before and after retreatment.RESULTS: Ten infants (18 eyes), of whom nine were referred from other hospitals, had persistence of Type 1 ROP in zone I or zone II despite previous laser treatment. Their mean gestational age was 24 weeks and their mean birth weight was 618 g. Seven eyes were diagnosed as stage 3 plus, eight eyes as stage 4A and three eyes as stage 4B. In eight infants (14 eyes), inadequate laser coagulation was suspected to be the cause for persistence of type 1 disease. Two infants (four eyes) were appreciated to have persistence of plus disease because of presence of zone I disease. For persistence of Type 1 ROP, five infants (seven eyes) were treated with vitrectomy, two infants (three eyes) with laser photocoagulation and anti-vascular endothelial growth factor (VEGF), two infants (four eyes) with anti-VEGF alone and finally two infants (four eyes) with laser photocoagulation alone. The anatomical outcome was good in 14 eyes and poor in four eyes (three infants).CONCLUSIONS: Inadequate laser coagulation is an important cause of treatment failure of ROP Type 1. Another cause is laser coagulation in zone I. To minimize remaining visual disability, some kind of centralization of the ROP treatment is suggested.
|
|
| 3. |
- Spandau, Ulrich, et al.
(author)
-
Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?
- 2013
-
In: Acta Ophthalmologica. - : Wiley. - 1755-375X .- 1755-3768. ; 91:2, s. 170-175
-
Journal article (peer-reviewed)abstract
- Purpose: To discuss treatment modalities for aggressive posterior retinopathy of prematurity (AP-ROP).Methods: The medical charts of all infants with AP-ROP at Uppsala University Hospital, Sweden, during a 2-year period (2009 and 2010) were reviewed. Eight infants (16 eyes) with a mean gestational age of 23.8 weeks and a mean birth weight of 592 g were treated with laser and/or intravitreal injections of bevacizumab (0.4 and 0.625 mg). RetCam photography was used to document the retinal appearance before and after treatment.Results: All infants (16 eyes) had AP-ROP in zone I. Mean time at initial treatment was 34 weeks postmenstrual age. Two eyes (one infant) were only treated with laser, and six eyes (three infants) were treated with laser therapy or cryopexy and, because of lack of regression, with bevacizumab as salvage therapy. Eight eyes (four infants) were treated with a first-line bevacizumab injection and four of these eyes (two infants) with additional laser ablation for continued disease progression in zone II. Macular dragging occurred in one eye of one infant primarily treated with laser.Conclusions: Given the high complication rate of the extensive laser treatment for zone I ROP, it is worth considering anti-vascular endothelial growth factor treatment as an alternative therapy. Further knowledge concerning side effects and long-term ocular and systemic outcome is warranted before this drug becomes general clinical practice.
|
|
